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Abstract: Melatonin is produced in the pineal gland as well as many other organs, including the 
enterochromaffin cells of the digestive mucosa. Melatonin is a powerful antioxidant that resists 
oxidative stress due to its capacity to directly scavenge reactive species, to modulate the 
antioxidant defense system by increasing the activities of antioxidant enzymes, and to stimulate 
the innate immune response through its direct and indirect actions. In addition, the dysregulation 
of the circadian system is observed to be related with alterations in colonic motility and cell 
disruptions due to the modifications of clock genes expression. In the gastrointestinal tract, the 
activities of melatonin are mediated by melatonin receptors (MT2), serotonin (5-HT), and 
cholecystokinin B (CCK2) receptors and via receptor-independent processes. The levels of 
melatonin in the gastrointestinal tract exceed by 10-100 times the blood concentrations.  Also, 
there is an estimated 400 times more melatonin in the gut than in the pineal gland.  Gut 
melatonin secretion is suggested to be influenced by the food intake. Low dose melatonin 
treatment accelerates intestinal transit time whereas high doses may decrease gut motility. 
Melatonin has been studied as a co-adjuvant treatment in several gastrointestinal diseases 
including irritable bowel syndrome (IBS), constipation-predominant IBS (IBS-C), diarrhea-
predominant IBS (IBS-D), Crohn‟s disease, ulcerative colitis, and necrotizing enterocolitis. The 
purpose of this review is to provide information regarding the potential benefits of melatonin as 
a co-adjuvant treatment in gastrointestinal diseases, especially IBS, Crohn‟s disease, ulcerative 
colitis, and necrotizing enterocolitis. 
Keywords: Gastrointestinal diseases; Crohn‟s disease; melatonin; ulcerative colitis; irritable 
bowel syndrome; necrotizing enterocolitis. 
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1. Introduction: 
 Gastrointestinal melatonin is produced by enterochromaffin cells (EC) of the digestive 
mucosa where its concentrations may exceed those in the blood [1]. One of melatonin‟s 
characteristics is its high lipophilicity allowing it to diffuse into deeper layers through the 
mucosa and submucosa, to act on the muscularis mucosae or the myenteric plexus. The amount 
of gastrointestinal (GIT) melatonin is estimated to be at least 400 times greater than in the 
pineal gland [2]. Its secretion from the EC cells may be influenced by food intake [3], its actions 
in the GIT are mediated by membrane receptors including (MT2), serotonin (5-HT) receptors, 
and its capacity of activate sympathetic neurons through the brain-gut connection system, and 
its antioxidant actions [4-8]. Melatonin produces smooth muscle relaxation by stimulating 5-
HT4 receptors, whereas it may also cause smooth muscle contraction by acting on 5-HT3 
receptors. 5-HT also modulates visceral sensation [6, 9]. Moreover, it was observed recently 
that melatonin may inhibit the activity of the serotonin transporter, which controls the reuptake 
of 5-HT by intestinal epithelial cells, and inhibits NK2 receptor-triggered 5-HT release by 
acting at a MT3 melatonin receptor located in the cells of the mucosal layer [10].  Low dose 
melatonin is also observed to accelerate intestinal transit time while high doses may decrease 
GIT motility by interacting with cholecystokinin B receptor (CCK2) and 5-HT3 receptors, 
present on the vagal afferent fibers inducing, via this means, vago-vagal inhibitory reflexes [3, 
4]. Those findings are supported by melatonin‟s modulatory role on gastric emptying due to its 
capacity to alleviate the inhibitory effect of the lipid related ileal break [11]. 
 Other roles related to motility regulation by melatonin have been suggested. The 
indoleamine reduces the nitrergic component of the smooth muscle inhibitory junction potential 
through a direct inhibition of nitric oxide synthase (NOS) activity at enteric synapses. Melatonin 
may also block nicotinic channels, or interact with Ca2+-activated K+ channels generating an 
inhibitory effect through an apamin-sensitive reaction [12, 13]. Melatonin also modulates 
acetylcholine-induced contractions of intestinal strips by an extracellular calcium dependent 
pathway [14]. In addition, melatonin may reverse lipopolysaccharide-induced motility 
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disturbances, which involves a reduction in lipid peroxidation and an increase of mitogen-
activated protein kinase activation, nuclear factor kappaB (NF-κB) activation, inducible NOS 
(iNOS) expression, and finally nitrite production [15].  Finally, melatonin regulates myoelectric 
activity by relaxing the bowel during phasic contractions [16]. 
 Antinociceptive effects of melatonin have been reported, but the mechanisms are not 
well defined. A recent study suggested that these actions of melatonin were probably not 
directly at the level of the GIT since luzindole (a non-specific MT1 and MT2 receptor 
antagonist), or naltrexone (a non-specific opioid receptor antagonist), blocked the 
antinociceptive actions; this suggested viscero-motor response and modulation of lumbosacral 
spinal neuronal activity [17]. 
 Gastrointestinal melatonin may also modulate the immune response by inhibiting 
macrophage activity through the reduction of NF-κB levels, COX-2 and iNOS activity; also, it 
modulates secretion elicited by prostaglandin E2 and regulates gene expression of 
proinflammatory cytokine levels including interleukins (IL-1), tumor necrosis factor alpha 
(TNF-α) and IFN-γ [18, 21]. In addition, gastrointestinal melatonin has antioxidant effects [22, 
23], reduces prostaglandin degradation by prostaglandin reductase and limits gastric lesions and 
hydrochloric acid secretion [22-24]; it also antagonizes 5-HT actions, which are related to 
gastric ulcer formation [3]. 
 Melatonin and its metabolites function as free radical scavengers and neutralize 
superoxide (O2
·-), hydrogen peroxide (H2O2), and the hydroxyl radical (·OH) [25-29], a highly 
reactive oxygen species (ROS)[30], as well as nitric oxide (NO·) and the peroxynitrite anion 
(ONOO·-) [31, 32], which are reactive nitrogen species (RNS) [33]. In addition, the indoleamine 
stimulates the cellular antioxidant defense system increasing mRNA levels and the activities of 
several important antioxidant enzymes including superoxide dismutase (SOD, which catalyzes 
the conversion of O2
·- to H2O2) and glutathione peroxidase (GPx) and glutathione reductase 
(GRd) [34-36]. Catalase (CAT) is also stimulated by melatonin and causes direct breakdown of 
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H2O2 to O2 and H2O [37, 38]. Moreover, the indoleamine inhibits iNOS, an enzyme involved in 
NO· generation [39]. Melatonin also promotes the synthesis of another important antioxidant, 
glutathione (GSH) [40] and it synergizes with other classic antioxidants to reduce oxidative 
damage [41]. Finally, melatonin chelates transition metals thereby reducing the formation of the 
highly toxic ·OH which significantly limits the number of essential molecules that are 
oxidatively mutilated [42, 43]. 
Herein, we summarize the protective actions of melatonin against several 
gastrointestinal diseases, including irritable bowel syndrome, Crohn‟s disease, ulcerative colitis, 
and necrotizing enterocolitis. To the authors‟ knowledge, this is the first review related to these 
subjects.  
 
2. Irritable bowel syndrome: 
Irritable bowel syndrome (IBS) is a common disorder (prevalence reported between 10-
20%) characterized by recurrent abdominal pain or discomfort, in combination with disturbed 
bowel habits in the absence of identifiable organic cause [44]. IBS is 3-fold more prevalent in 
women than in men, and in the postmenopausal period this number increases to 6-fold. This 
may be a consequence of drop in melatonin secretion preceded by the rise in follicle-stimulating 
hormone (FSH) concentration in postmenopausal women [45, 46]. Its pathophysiology has been 
associated with abnormal gastrointestinal motor functions, visceral hypersensitivity, 
psychosocial factors, autonomic dysfunction, mucosal inflammation, and intestinal microbiota 
imbalance [47, 48]. Moreover, corticotropin releasing factor (CRF) is released during stress, and 
stimulates colonic motor activity via either central [49, 50] or peripheral CRF receptors [51] 
resulting in colon hyperkinesis. Depending of the IBS predominant symptoms, there are two 
clinical types: constipation predominant IBS (IBS-C) and diarrhea-predominant IBS (IBS-D). 
IBS-D is associated with reduced 5-HT reuptake, while IBS-C is related with lack of 5-HT 
release [9].  
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 Sleep disorders are also present in 26–55% of IBS patients [52] and are related to rapid 
eye movement (REM) sleep modifications [53]. In addition, the severity of IBS symptoms is 
observed to vary with the quality of the previous night‟s sleep [54]. It is suggested that sleep 
disorders are a result of an increase in the activity of the kynurenine pathway (a tryptophan 
metabolite) (Figure 1) with a reduction in the serotonin/melatonin pathway [55-57]. This theory 
was considered since some studies reported reduced ratios of kynurenine/tryptophan in IBS 
patients [58]. One human study observed increased cortisol levels with a reduced 
melatonin/tryptophan ratio in IBS [58]. The mechanisms responsible for the sleep disorders in 
IBS patients remain unexplained. 
 6-Hydroxymelatonin sulphate (6-OHMs) is a hepatic metabolite of melatonin that is 
excreted in the urine.  Urinary levels of 6-OHMs over a 24-hour period correlate well with 
plasma melatonin levels [59]. Human studies reported increased levels of 6-OHMs in 
premenopausal and postmenopausal women afflicted with IBS-C or IBS-D [60]. The authors 
did not observed significant statistical differences between IBS-C symptoms in premenopausal 
and postmenopausal females and the excretion of 6-OHMs, but a slight increase in levels of 
metabolite excretion was observed in patients with moderate symptoms. 6-OHMs, 
concentrations were found to be higher in postmenopausal women affected with IBS-D than in 
premenopausal females with a large increase in women with exacerbated symptoms. These 
results support the theory that melatonin levels in IBS women are lowered after menopause [61, 
62]. Salivary melatonin levels, which are also well correlated with melatonin plasma 
concentrations [63], are reduced in IBS patients. The salivary melatonin concentrations increase 
if melatonin is orally administered [63]. 
 Physicians usually treat IBS with antispasmodics, psychopharmacological treatments, 
psychotherapy, and newer drugs such as linaclotide, prucalopride, tegaserod, and lubiprostone, 
but disparate results are observed [64]. Antagonists of the serotonin 5-HT3 receptor are usually 
used in patients affected with IBS-D, whereas the partial agonist of serotonin 5-HT4 receptor 
alleviates symptoms of IBS-C [65, 66]. It is suggested that melatonin treatment may play an 
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important role in the regulation of intestinal motility by inhibiting nicotinic channels in the 
neurons of the submucosal plexus to regulate the cholinergic transmission and relax muscle 
contraction through an interaction with small conductance K+-channels [12, 67], or by inhibiting 
the activity of 5-HT and CRF, which are increased in IBS patients [68]. 
 Water avoidance stress generates motility disorders and increases fecal output [69]. In 
one study it was also observed that melatonin (10 mg/kg i.p.) attenuated the fecal output and 
reduced the dry weight of the stool. Furthermore, 5-HT serum levels were depressed in 
melatonin-treated animals suggesting that the modulatory effect may be mediated through the 5-
HT pathway. Melatonin also was observed to lower the amplitude of spontaneous contractions 
of colonic smooth muscle strips as well as ACH-induced and K l-mediated contractions. This 
was presumed to be due to an interaction between melatonin and Ca2+-activated calmodulin 
preventing the latter from activating myosin light-chain kinase and inducing a reduced muscle 
contraction [70]. K+-induced contractions are attributed to a Ca2+ effect [71].  Melatonin may 
have reduced the influx of calcium. 
 Oral melatonin (3 mg) treatment has been also observed to significantly increase colonic 
transit time of healthy subjects [72]. A similar effect was observed in IBS patients, as in 
previous studies [63, 68], suggesting a predominant beneficial effect of melatonin in IBS-C 
patients.  
 In reference to abdominal pain, it was observed that 3 mg of melatonin given orally for 
2 weeks significantly reduced the discomfort with a tendency towards a greater reduction of 
abdominal distension, stool frequency, and total bowel symptoms. The authors also observed 
that rectal distension pressure and volume thresholds, which induce the sensations of urgency 
and pain, were significantly decreased [73]. Similar beneficial effects were obtained in a study 
in which melatonin improved the quality of life due to the modulation of colonic symptoms 
including pain severity and frequency, bloating, bowel habit dissatisfaction, and life 
interference. Extracolonic IBS symptoms such as headache, lethargy, nausea, early satiety, or 
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urinary disturbances were also improved [74]. Chojnacki et al. [62], in a recent study in 
postmenopausal women, observed that melatonin therapy significantly reduced pain and 
abdominal bloating in IBS-C patients.  The authors did not find similar results in IBS-D patients 
or modifications in colonic transit time in either IBS-C or IBS-D subjects. In their study, 
researchers gave melatonin twice daily (in the morning and in the evening).  Thus, they deduced 
that melatonin administration in a divided dose may be more effective because of melatonin‟s 
short half-life (30−60 min.) [75]. IBS patients usually have symptoms during the day and rarely 
at night. 
 
3. Crohn’s disease 
Inflammatory bowel diseases (IBD) include Crohn‟s disease (CD) and ulcerative colitis 
(UC), both chronic inflammatory disorders of the gastrointestinal tract which are characterized 
by a relapsing and remitting course [76]. In the United States, CD incidence is estimated to be 
6-8 per 100,000, with a prevalence of 100-200 per 100,000 [77]. IBD is a result of a 
miscommunication between the gut microbiota and the intestinal mucosal immune system, 
resulting in the failure of mucosal homeostasis. The integrity of the epithelial barrier, 
determined by genetic defects, and the presence of triggering environmental factors are also 
required to generate chronic inflammation [78]. A genetic polymorphism is not sufficient alone 
to generate the inflammatory phenotype of IBD [79]. Smoking is observed to be protective for 
UC and harmful for CD [80]. Moreover, drugs, stress, and dietary habits are also related with 
IBD pathogenesis [81]. Two recent studies show that melatonin in the gut microbiome may 
relate to melatonin‟s beneficial actions in patients with IBD [82, 83]. 
 Like UC, there exists a relationship between sleep quality and colon disease activity. A 
poor sleep quality and fatigue are common in clinically active disease compared with inactive 
disease patients [84, 85]. This effect is more pronounced in those patients with CD compared 
with UC patients. In addition, it was observed that CD patients with impaired sleep have a two-
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fold greater risk of active disease in 6 months, whereas no such relationship has been described 
in UC patients [86]. Furthermore, symptoms activity is increased in the mornings following a 
poor night of sleep, and this effect is also more usual in CD patients [87]. However, the 
relationship between sleep disorders and CD and UC diseases are poorly understood [88]. 
Figure 2 summarizes these relations.   
 Melatonin treatment for CD is rare. We found a single article related to the effects of 
melatonin (3 mg) in a CD patient [89]. The authors observed disease activation after melatonin 
treatment in a single previously inactive patient. 24 hours after stopping melatonin treatment, 
the symptoms abated. The authors suggested that melatonin may have activated a number of 
cytokines (i.e., IL-2 and IL-12) which could have exacerbated the symptoms. This presumption 
is based on the findings that Th1 and Th17 pathways appear to predominate in the inflamed 
mucosa of CD patients, whereas Th2 and Th17 factors are abundant in UC [90]. Moreover, it is 
known that Th1 increases the IFN-γ production in CD [91], and CD patients exhibit elevated 
lamina propria IL-12 production as compared to controls [92]. Melatonin promotes a Th1-
response by increasing IL-12 and IFN-γ levels [93, 94]. The observations of Calvo and co-
workers [89] require additional studies in a larger population of CD patients. 
 JAK kinase family is associated with intracellular signaling, which is initiated by the 
action of various cytokines. When JAK kinase activity is blocked, this cascade is suspended 
[95]. Usual treatments such as tofacitinib inhibit JAK1 and JAK3 [96]. A recent study suggested 
that Neu-P11 (piromelatine, N-(2-(5-methoxy-1H-indol-3-yl)ethyl)-4-oxo-4H-pyran-2 
carboxamide), a novel melatonin (MT1/MT2) and 5-HT1A/1D receptor agonist [97] protected 
the cells via activation of the JAK2 survival pathway [98]. A recent meta-analysis determined 
that a JAK2 rs10758669 polymorphism was significantly associated with CD and UC 
susceptibility [99]. Moreover, it is known that the activation of JAK2 in IL-R receptor results in 
the phosphorylation of STAT3 in activated macrophages and dendritic cells [100]. In IBD, 
JAK2/STAT3 pathway interferes with Th1, Th2, and Th17 cells [101, 102]. 
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 SMAD7 and SMAD2 also act as inhibitors of TGF-β1 and were found to be upregulated 
in CD [103, 104]. New CD treatments such as mongersen inhibits SMAD7 expression thereby 
restoring TGF-β1 levels; this leads to the suppression of inflammatory cytokine production 
[104]. Melatonin also inhibits SMAD6 and SMAD7 expression, but facilitates SMAD2 
activation [105]. In addition, miR-200b prevents this effect by targeting SMAD2, but its levels 
are inversely correlated with the TGF-β1 levels in IBD [103]. Recent studies showed that failure 
of the integrity of the intestinal epithelial barrier may be an early event in the natural history of 
IBD; this allows for the uncontrolled influx of bacterial products into the lamina propria and the 
propagation of proinflammatory mucosal responses [106]. 
 TGF-β and IL-6 are also important inducers of Th17 cells producing IL-17 and IL-22. 
IL-23 interacts with differentiated Th17 cells and causes “stabilization” and/or expansion of 
Th17 cells [107-109]. In vitro, the addition of melatonin suppresses the polarization of human T 
helper cells into the Th17 lineage [110]. However, IL-23p19 deficient mice exhibit increased 
numbers of regulatory T cells (Foxp3+ T cells) [111, 112] and, because of this, CD may develop 
because of the observed important role of Th1 pathway which causes an 40-fold greater IFN-γ 
production compare to that induced by IL-17 production [113, 114]. 
 
4. Ulcerative colitis: 
The incidence of UC is estimated to be 9-12 per 100,000, with a prevalence of 205-240 
per 100,000 [77]. Moreover, approximately 20 percent of people with UC have a close relative 
with IBD [115]. Like CD, the integrity of the epithelial barrier, genetic polymorphisms, and the 
presence of triggering environmental factors are required to generate the chronic inflammation 
[78]. Moreover, the incidence of colon cancer is increased in patients with UC, and the risk of 
colitis-associated colon carcinogenesis (CACC) augments with increased extent and duration of 
UC [116]. As stated above, Th2 and Th17 pathways are predominant in UC [90]. In addition, 
IBD-specific changes in the gut microbiota play an important role in UC disease and, because of 
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that, antibiotics or probiotics may be not effective in some cases [117]. However, probiotics like 
VSL#3 have high efficacy in preventing the development or recurrence of pouchitis in patients 
with UC who have undergone ileal-pouch-anal anastomosis [118]. The epithelial barrier also 
plays an important role in UC and treatment with phosphatidylcholine may restore barrier 
function and ameliorate intestinal inflammation [119]. Molecules such as tofacitinib, which 
inhibits JAK1 and JAK3, and several cytokines [78], are effective anti-inflammatory treatments 
in UC due to inhibition of the differentiation of effector lymphocytes of the Th2 and Th17 types 
[120]. Elevated IL-4, IL-13, and TGF-β levels are associated with the Th2 pathway [90, 121]. 
Vedolizumab is a humanized monoclonal antibody with anti-efficacy inflammatory effects on 
the gut without affecting trafficking of other sites [122]. Etrolizumab also has demonstrated 
beneficial effects against UC disease [123].  
 The number of myenteric neurons is reduced in patients affected with UC disease [124]. 
Nuclear factor erythroid 2-related factor 2 (Nrf2) is a protective factor for different cells and 
tissues against inflammation and oxidative stress [125]. Nrf2 deficiency is observed to increase 
oxidative stress and inflammatory processes through an increased production of COX-2, iNOS, 
IL-1β, IL-6, and TNF-α. Furthermore, in these situations, decreased expression of 
antioxidant/phase II detoxifying enzymes such as heme oxygenase-1 (HO-1), quinone 
oxidoreductase (NQO-1), UDP-glucuronosyltransferase 1A1, and GST Mu-1 is observed [126]. 
It is known that, under oxidative stress conditions, Nrf2 is released from its repressor Kelch-like 
ECH-associated protein 1 (Keap1) and transforms into its activated form; this results in an 
activation of antioxidants or detoxifying enzymes [127]. Several studies reported that melatonin 
regulates Nrf2 expression [128-130]. In rats, Nrf2 expression is reduced in UC [131]. In this 
study, melatonin upregulated Nrf2 expression thereby ameliorating the histopathological 
disturbances, including the preservation of myenteric neurons, which play an important role in 
the regulation of motility and sensitivity of the intestine. 
 EC proliferation, hydroxyindole-O-methyltransferase (HIOMT) expression (an enzyme 
involved in melatonin synthesis), and increased urine excretion of 6-OHMs is apparent in the 
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acute phases of ulcerative proctitis and UC. Consequently, the augmentation of melatonin 
secretion may have a beneficial effect in anti-inflammatory and defense mechanisms [132]. 
Melatonin levels are typically lower in active patients than in patients in remission [133]. 
 Sleep deprivation plays an important role in UC by downregulating gene expression. 
These disturbances are reduced after using melatonin (10 mg/kg i.p.) [134]. In addition, 
microvascular thrombosis and oxygen free radical-induced injury are known to be important in 
UC pathogenesis [135, 136]. UC is a Th2 and Th17-like disease associated with increased IL-13 
production [137]. IL-17 levels are also elevated in UC due to Th17 activity, but its levels are 
lower in CD [114]. IL-13, IL-4, and TGF-β levels are also increased in an oxazolone-colitis 
model; however, IFN-γ levels remain normal [138, 139]. IL-13 is the most important cytokine 
involved in UC disease. As a result, treatments such as IFN-β are effective in this illness 
through a reduction in IL-13 levels [121]. Unlike in CD, melatonin may be effective in the 
treatment of UC via its capacity of attenuate IL-13 levels [140]. In addition, elevated 
homocysteine (HCY) concentrations stimulate vascular smooth muscle cell proliferation, 
increase collagen formation and deposition, lead to vascular stenosis and accelerate thrombosis 
[141, 142]. UC patients have increased plasma and intestinal mucosal levels of HCY [143-145] 
with reduced levels of melatonin [132]. HCY inhibits GPx levels, decreases NO· bioavailability, 
and generates H2O2
 [146]. However, a relationship between melatonin and HCY levels was not 
observed [132]. 
 Melatonin has been studied as a UC adjuvant treatment. Melatonin benefits against UC 
syndrome are summarized in table 1. The findings indicate melatonin may reverse the macro- 
and microscopic lesions. This relates to melatonin‟s capacity to limit lipid peroxidation (LPO), 
myeloperoxidase activity (MPO), reduce inflammatory cytokine levels, and stimulate 
antioxidant enzymes; these are all oxidative stress markers and are modified during UC [54, 
164]. Moreover, STAT-3, an important mediator in IBD, is elevated during UC since this 
disease is associated with elevated levels of IL-6, which induces STAT3 [165, 166]. NF-κB is 
important for the inflammatory process; low levels of peroxides induce its activation whereas 
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some antioxidants reduce its translocation [167, 168]. NF-κB upregulates the expression of 
TNF-α, IL-1β, iNOS, and COX-2 [169]. Elevated pentraxin-3 (PTX-3) levels, an acute phase 
protein related to C-reactive protein, is present during inflammatory conditions [170], and a 
reduction of PTX-3 gene activity results in an inflammatory process in the vascular wall with 
augmented macrophage accumulation [171]. Moreover, PTX-3 is involved in immune defense 
in inflamed colon tissue, in particular, in crypt abscess lesions of patients with UC [172]. As 
summarized in table 1, melatonin reportedly attenuates inflammatory processes thereby 
alleviating colitis. 
 Melatonin treatment also significantly enhances expression of Nrf2 and NQO-1, while 
decreasing matrix metalloproteinase-9 [158]. All these are markers of oxidative stress [173-
175]. MMPs mediate cellular infiltration, cytokine activation, cell migration, tissue damage, 
remodeling and repair [176]. TNF-α stimulates MMP-9 expression while melatonin reduces the 
levels of this cytokine [147]. 
 From the findings summarized in table 1, one report indicates a detrimental effect of 
melatonin (1-2 mg/kg) in the evolution of the lesions, levels of TNF-α and MPO activity as well 
as the hydroxyproline production, an indicator of fibrosis [144]. This latter parameter may be of 
special interest because fibrosis is a major complication of IBD [177]. These differential effects 
may be a consequence of diurnal variations of melatonin binding sites during the day [178], 
with a maximal affinity of the receptors detected in the evening [179]. It is also known that the 
capacity of melatonin to stimulate gene expression of antioxidant enzymes controls biorhythms 
[180]. This is consistent with observations in a gastric model of damage that involved ischemia–
reperfusion, where melatonin clearly diminished the number and severity of the ulcers in 
animals treated late in the afternoon while no protection was detected when treatments were 
applied in the morning [181]. Perhaps the articles with the greatest importance in table 1 are the 
human studies, which yielded good results when melatonin was used in addition to mesalazine; 
this suggests a new therapeutic option for this disease. 
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 Melatonin benefits against colitis-associated colon carcinogenesis (CACC) have been 
uncovered. In a mouse model, melatonin (1 mg/kg) reduced inflammatory markers (MPO, IL-
17, IL-6, TNF-α, NF-Kβ, STAT-3, and COX-2), oxidative stress markers (TBARS), autophagy 
markers (including Beclin-1, LC3B-II/LC3B-I ratio and p62), and DNA damage. Conversely, 
Nrf2, HO-1, and NQO-1 expression were elevated by melatonin. The benefits of melatonin were 
also reflected at the histopathological level with a decrease of tumor frequency and dysfunction 
of calcium-activated calcium channels.  The findings indicate that reduced inflammation and 
oxidative stress due to melatonin intervention in mice inhibits autophagy and prevents CACC 
malfunctions [182]. 
 
5. Necrotizing enterocolitis 
Necrotizing enterocolitis (NEC) is the most common neonatal gastrointestinal 
emergency requiring surgical intervention [183, 184]. The prevalence of the disorder is about 
7% among infants with a birth weight between 500 and 1500 g, and the estimated rate of death 
is between 20 and 30% [185].The pathogenesis of NEC is likely multifactorial, including 
immature gut function, impaired intestinal barrier, disturbed gastrointestinal motility, and 
circulatory factors [186]. Platelet-activating factor, intestinal toll-like receptors, TNF-α, 
interleukins (IL-1β, IL-6, IL-8, IL-10, IL-12), lipopolysaccharide, nitric oxide (NO), and 
oxygen-derived free radicals may also play pivotal roles in NEC pathogenesis [187-191]. In a 
preterm infant study [192], the authors measured non-protein bound iron (a marker of potential 
oxidative stress risk), and markers of free radical damage (advanced oxidation protein products 
and total hydroperoxides) in the cord blood and observed these were significantly higher in 
babies with NEC than in healthy infants. Moreover, they reported that toll-like receptor-4 is a 
crucial component of NEC vulnerability [193]. 
 Human neonates, especially those born prematurely, have an incompletely developed 
system to detoxify free radicals [194]. Thus, treatments that modulate antioxidative defense and 
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anti-inflammatory protection including hyperbaric oxygen [195], medical ozone [196],  
N-acetylcysteine [197], and glutamine alone or in conjunction with arginine [198] have been 
studied. Melatonin, a molecule that clearly upregulates these systems, ameliorated oxidative 
stress by reducing MDA levels, an index of lipid peroxidation [199], protein carbonyl content, 
TNF-α, and IL-1β levels, and stimulated SOD and GPx activities in a rat model of NEC [200]. 
Melatonin treatment combined with PGE1 [201], a cytoprotective agent in the gastrointestinal 
system mucosa, had a preventive effect against bacterial invasion and reduced inflammation and 
tissue injury [2020, 203]. Each provided preventive effects individually but melatonin was more 
effective in reducing MDA levels and elevating SOD and GPx activities. These results were 
also reflected at histopathological level.  The best results were observed using melatonin and PG 
concurrently. 
 
6. Conclusions: 
 IBD and IBS patients exhibit poor sleep quality and reduced levels of melatonin. 
Moreover, gender and aging are important risk factors for individuals suffering with IBS, with 
women exhibiting this disease more frequently than men. In IBS-C, melatonin improves life 
quality and decreases pain. In IBS-D patients the benefits of melatonin are much less apparent 
possibly because 5-HT receptors play a different role in this pathology. IBD has more 
similarities to UC, since Th2 and Th17 are involved in both and melatonin has beneficial effects 
by modulating these pathways. Recent studies also suggest that melatonin may be effective in 
preventing the progression of colitis-associated colon carcinogenesis due to its capacity to 
attenuate the induction of autophagy. In contrast, Th1 and Th17 are the major pathways 
involved in CD, and melatonin increases Th1 activity which induces more injury in the affected 
tissues. More studies are necessary to identify the potential beneficial effects of melatonin in 
these illnesses.  The potential of melatonin as a treatment for these conditions should be pursued 
because the usual treatments are not often effective and may have negative secondary effects. 
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Melatonin may be effective when given in combination with the routinely-used drugs, if for no 
other reason than, to reduce the side effects of those medications. 
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Figure 1: Kynurine and melatonin pathways. It is suggested that sleep disorders generated in 
patients affected of irritable bowel syndrome are a result of an increase in the activity of the 
kynurenine pathway with a reduction in the serotonin/melatonin pathway.  
Figure 2: Sleep disruption increases ulcerative colitis and Crohn‟s disease disturbs. However, 
these alterations may also induce sleep disruption, generating a loop not well understood yet.  
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Table 1: Studies related to melatonin‟s benefits in ulcerative colitis (UC).  MEL, Melatonin, 
MPO; myeloperoxidase, MDA; malondialdehyde, iNOS; inducible nitric oxide synthase, NO·; 
nitric oxide, PGE2; prostaglandin, E2; GSH, glutathione, MMP, matrix metallopeptidase; SOD, 
superoxide dismutase; PTX-3: pentraxin-3.  
Studies Model Melatonin dose Comments 
Cuzzocrea et al., 2001 
[147] 
Dinitrobenzene 
sulfonic acid 
(DNBS)–induced 
colitis in rats 
15 mg/kg i.p. MEL ameliorated the disruption of the colonic architecture, reduced MPO activity, MDA 
levels, appearance of nitrotyrosine, PARS immunoreactivity, ICAM-1 expression, and the 
expression of P-selectin. Staining degree of COX-2 and iNOS were also reduced. 
Dong et al., 2003 
[148] 
Acetic-acid (AA) or 
trinitrobenzene 
sulfonic  acid 
(TNBS)-induced 
colitis in rats 
2.5, 5.0, 10.0mg/kg i.c. MEL, in a dose-dependent manner, inhibit iNOS and COX-2 expression, decreased NO· 
and PGE2 levels,  
Li et al., 200 [149] TNBS-induced 
colitis in rats 
2.5, 5.0, 10.0mg/kg i.c. MEL treatment, in a dose-dependent manner, reduced macro/microscopic lesions, TNF-α, 
and ICAM-1 protein expression, and NF-κB activation. MEL 10 mg/kg obtained similar 
results to 5-aminosalicylic acid (5-ASA) group.  
Mei et al., 2005 [150] TNBS-induced 
colitis in rats 
2.5, 5.0, 10.0mg/kg i.c. MEL, in a dose-dependent manner, attenuates macro/microscopic lesions, reduced MPO 
activity, MDA, and NO· levels.  
Marquez et al.,2006 
[151] 
TNBS-induced 
colitis in rats 
0,5 mg/kg, 1 mg/kg and 2 
mg/kg i.p. 
MEL, in a dose-dependent manner, attenuates macroscopic lesions, body weight loss, and 
fibrosis markers expression. TNF-α level and MPO activity were also reduced due to MEL 
effect. Detrimental effects were observed in long-term treated animals (21 days). 
Mazzon et al., 2006 
[152] 
DNBS–induced 
colitis in rats 
15 mg/kg i.p. MEL attenuates macro/microscopic lesions, reduced the degree of the expression of JNK, 
attenuates TNF-α and IL-1β levels, and NF-κB, Bcl-2 and Bax expression.  
Nosál'ová et al., 2007 
[153] 
AA-induced colitis 
in rats 
5 mg/kg and 10 mg/kg 
i.p.or i.c. 
In a dose-dependent manner, MEL reduced macroscopic lesions, increased GSH levels, 
and decreased MPO activity. 
Esposito et al., 2008 
[154] 
DNBS–induced 
colitis in rats 
15 mg/kg i.p.  MEL treatment reduced macro/microscopic lesions, MDA levels and TNF-α level. MEL 
also reduced MMP-2 and MMP-9 activities after DNBS-induced colitis.   
Akcan et al., 2008  
[155] 
TNBS-induced 
colitis in rats 
10 mg/kg i.p.  MEL treatment reduced macro/microscopic lesions, TNF-α level, MPO and caspase-3 
activities, and bacterial translocation.  
Tahan et al., 2010 
[156] 
AA-induced colitis 
in rats 
100 mg/kg i.p. AA produced macro/microscopic lesions, increased MPO activity, and increased MDA, 
IL-1β, IL-6, and TNF-α levels. MEL attenuates significant statistical all these disturbs. 
GSH and SOD activity were also increased. 
Sayyed et al., 2013 
[157] 
AA-induced colitis 
in rats 
10 mg/kg i.p. Groups: 
Pre-treatment during 15 
days, treatment after 15 
days, treatment after 4 
weeks 
MEL treatment reduced macro/microscopic lesions, and maintain body and colon weight. 
MEL also attenuates the positive staining of NF-κb, the increased PTX-3 and lipid 
peroxides serum levels, and the decreased thiols levels. These changes are present due to 
AA effect. MEL short treatment was the most effective group. 
Trivedi and Jenna, 
2013 [158] 
Dextran sulfate 
sodium (DSS)-
induced colitis in 
rats 
2 mg/kg, 4 mg/kg, 8 
mg/kg orally 
MEL, in a dose-dependent manner, decreased UC activity, increased colon length, 
decreased MPO activity, NF-Κb, COX-2 and STAT3 levels, increased IL.6, IL-17 and 
TNF-α levels, reduced oxidative stress cytokine levels and DNA damage, and attenuates 
fibrosis.  
Chung et al., 2014 
[142] 
DSS-induced colitis 
with sleep 
deprivation in rats 
10 mg/kg i.p. MEL not recovered weight loss, but prevented weight loss and gene modification due to 
DSS-induced colitis + sleep deprivation. 
Esiringü et al., 2015 
[159] 
AA-induced colitis 
in rats 
Intracolonic melatonin 
gel  
MEL attenuates NO· levels and histological lesions, but any effects were showed in MDA 
and GSH levels.  
Trivedi et al., 2015 
[160] 
DSS-induced colitis 
associated colon 
carcinogenesis 
1 mg/kg i.p. MEL reduced UC activity, tumor multiplicity, and progression of colon carcinogenesis, 
caused a significant decrease in NF-κB, COX-2, and STAT3 levels, attenuates oxidative 
stress, autophagy and DNA damage, and caused a significant increase in Nrf2, NQO-1, 
and HO-1 levels. 
Shang et al., 2016 
[130] 
DNBS–induced 
colitis in rats 
2.5 mg/kg i.p.  MEL ameliorated the histopathological disturbs caused by DNBS, reduced MDA SOD, 
and MPO levels. Nrf2 and HO-1 reduced expression due to DNBS was modified in MEL 
rats with an upregulation of its levels. 
Tasdemir et al., 2011 
[161] 
DNBS–induced 
colitis in rats 
MEL 5mg/kg i.p. + 
erythropoietin (EPO) 
(1000 IU/kg s.c.) 
MEL groups obtained better results than EPO groups reducing histological injury, CD4 
and CD8 expression. However, MEL + EPO groups showed better results than these 
antioxidants alone. 
Mann, 2003 [162] Human model 3 mg orally UC activity was reduced during MEL treatment 
Maldonado and 
Calvo, 2008 [163] 
Human model 3 mg orally MEL triggers UC symptoms. After 24-48h of the stop of melatonin consumption, UC 
activity ceased. 
Chojnacki et al., 2011 
[132] 
Human model 5 mg orally  MEL reduced UC activity, c-reactive protein levels, and attenuates the decreased 
hemoglobin concentration in blood observed in non-melatonin treatment group. 
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